Table 1. Clinical information for human CSF samples.
Subject ID | HD status | Sex | Age | CAG size | Disease burden | Age of onset | UHDRS motor | Verbal fluency | SDMT | Stroop colour | MFI |
---|---|---|---|---|---|---|---|---|---|---|---|
13 | Control | Female | 29 | 18 | 0 | 32 | 53 | 80 | −5.00 | ||
21 | Control | Male | 55 | 17 | 0 | 28 | 41 | 78 | 17.00 | ||
23 | Control | Female | 47 | 17 | 0 | 39 | 57 | 100 | −9.00 | ||
27 | Control | Female | 66 | 21 | 0 | 38 | 48 | 80 | 13.50 | ||
28 | Control | Female | 38 | 20 | 0 | 45 | 44 | 73 | 49.00 | ||
29 | Control | Female | 58 | 17 | 0 | 48 | 60 | 88 | 38.00 | ||
30 | Control | Male | 27 | 17 | 0 | 55 | 56 | 88 | −29.00 | ||
31 | premanifest | Male | 39 | 45 | 370.5 | 41* | 2 | 35 | 29 | 52 | 63.00 |
32 | premanifest | Female | 33 | 44 | 280.5 | 44* | 0 | 58 | 48 | 80 | 31.00 |
33 | premanifest | Male | 30 | 42 | 195 | 52* | 0 | 43 | 59 | 81 | 77.00 |
35 | premanifest | Male | 57 | 41 | 313.5 | 57* | 5 | 34 | 36 | 59 | 193.00 |
37 | premanifest | Male | 27 | 44 | 229.5 | 41* | 1 | 35 | 47 | 72 | 255.00 |
39 | premanifest | Female | 68 | 36 | 34 | 85* | 0 | 50 | 45 | 83 | −35.00 |
41 | premanifest | Female | 39 | 45 | 370.5 | 41* | 8 | 42 | 38 | 54 | 332.00 |
42 | premanifest | Female | 38 | 45 | 361 | 41* | 6 | 49 | 45 | 59 | 369.50 |
48 | premanifest | Male | 40 | 43 | 300 | 48* | 4 | 53 | 50 | 70 | 207.00 |
49 | premanifest | Female | 23 | 40 | 103.5 | 63* | 1 | 53 | 64 | 83 | 40.00 |
15 | Early | Female | 43 | 47 | 494.5 | 34 | 29 | 26 | 34 | 50 | 341.50 |
18 | Early | Female | 56 | 39 | 196 | 45 | 22 | 70 | 57 | 87 | 107.50 |
19 | Early | Male | 44 | 46 | 462 | 41 | 24 | 22 | 30 | 70 | 52.00 |
25 | Early | Male | 42 | 44 | 357 | 31 | 27 | 23 | 20 | 40 | 314.50 |
16 | Mid | Male | 72 | 41 | 396 | 60 | 61 | 27 | 17 | 40 | 285.00 |
17 | Mid | Male | 51 | 45 | 484.5 | 43 | 54 | 20 | 13 | 24 | 505.50 |
20 | Mid | Male | 51 | 43 | 382.5 | 44 | 54 | 20 | 21 | 34 | 465.50 |
22 | Mid | Male | 53 | 43 | 397.5 | 35 | 41 | 38 | 26 | 55 | 15.00 |
24 | Mid | Female | 45 | 43 | 337.5 | 38 | 29 | 56 | 33 | 57 | 97.50 |
26 | Mid | Male | 56 | 37 | 84 | 46 | 57 | 12 | 13 | 19 | 455.00 |
34 | Late | Male | 53 | 46 | 556.5 | 38 | 53 | 213.00 | |||
36 | Late | Female | 46 | 47 | 529 | 35 | 78 | 164.00 | |||
38 | Late | Male | 63 | 44 | 535.5 | 54 | 60 | 67.00 | |||
40 | Late | Female | 46 | 40 | 207 | 39 | 53 | 147.00 | |||
43 | Late | Male | 66 | 44 | 561 | 50 | 94 | 123.00 | |||
44 | Late | Female | 67 | 48 | 837.5 | 40 | 96 | 346.50 | |||
45 | Late | Female | 48 | 48 | 600 | 36 | 86 | 474.00 | |||
46 | Late | Female | 60 | 43 | 450 | 47 | 94 | 209.00 | |||
47 | Late | Male | 66 | 42 | 429 | 47 | 74 | 71.00 | |||
50 | Late | Male | 29 | 63 | 797.5 | 18 | 72 | 474.00 |
MFI-median fluorescence intensity, SDMT-symbol digit modality test, UHDRS-universal Huntington disease rating scale.
*predicted2.